A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma


Background:
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an urgent need to better identify patients who have the most aggressive disease.

Methods and Findings:
We analyzed the gene expression profiles of primary tumors from patients with localized compared to metastatic disease and identified a six-gene signature associated with metastatic disease. We evaluated the prognostic potential of this signature in a training set of 34 patients with localized and resected PDAC and selected a cut-point associated with outcome using X-tile. We then applied this cut-point to an independent test set of 67 patients with localized and resected PDAC and found that our signature was independently predictive of survival and superior to established clinical prognostic factors such as grade, tumor size, and nodal status, with a hazard ratio of 4.1 (95% confidence interval [CI] 1.7–10.0). Patients defined to be high-risk patients by the six-gene signature had a 1-year survival rate of 55% compared to 91% in the low-risk group.

Conclusions:
Our six-gene signature may be used to better stage PDAC patients and assist in the difficult treatment decisions of surgery and to select patients whose tumor biology may benefit most from neoadjuvant therapy. The use of this six-gene signature should be investigated in prospective patient cohorts, and if confirmed, in future PDAC clinical trials, its potential as a biomarker should be investigated. Genes in this signature, or the pathways that they fall into, may represent new therapeutic targets.

: Please see later in the article for the Editors' Summary


Vyšlo v časopise: A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma. PLoS Med 7(7): e32767. doi:10.1371/journal.pmed.1000307
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1000307

Souhrn

Background:
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an urgent need to better identify patients who have the most aggressive disease.

Methods and Findings:
We analyzed the gene expression profiles of primary tumors from patients with localized compared to metastatic disease and identified a six-gene signature associated with metastatic disease. We evaluated the prognostic potential of this signature in a training set of 34 patients with localized and resected PDAC and selected a cut-point associated with outcome using X-tile. We then applied this cut-point to an independent test set of 67 patients with localized and resected PDAC and found that our signature was independently predictive of survival and superior to established clinical prognostic factors such as grade, tumor size, and nodal status, with a hazard ratio of 4.1 (95% confidence interval [CI] 1.7–10.0). Patients defined to be high-risk patients by the six-gene signature had a 1-year survival rate of 55% compared to 91% in the low-risk group.

Conclusions:
Our six-gene signature may be used to better stage PDAC patients and assist in the difficult treatment decisions of surgery and to select patients whose tumor biology may benefit most from neoadjuvant therapy. The use of this six-gene signature should be investigated in prospective patient cohorts, and if confirmed, in future PDAC clinical trials, its potential as a biomarker should be investigated. Genes in this signature, or the pathways that they fall into, may represent new therapeutic targets.

: Please see later in the article for the Editors' Summary


Zdroje

1. BoyleP

LevinB

2008 World Cancer Report 2008. Lyon International Agency for Research on Cancer

2. ParkinDM

BrayF

FerlayJ

PisaniP

2005 Global cancer statistics, 2002. CA Cancer J Clin 55 74 108

3. NeuhausP

RiessH

PostS

GellertK

RidwelskiK

2008 CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings 26 LBA4504

4. FerroneCR

BrennanMF

GonenM

CoitDG

FongY

2008 Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12 701 706

5. ConlonKC

KlimstraDS

BrennanMF

1996 Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223 273 279

6. SchnelldorferT

WareAL

SarrMG

SmyrkTC

ZhangL

2008 Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247 456 462

7. ClearySP

GryfeR

GuindiM

GreigP

SmithL

2004 Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198 722 731

8. HanSS

JangJY

KimSW

KimWH

LeeKU

2006 Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32 271 275

9. WinterJM

CameronJL

CampbellKA

ArnoldMA

ChangDC

2006 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10 1199 1210; discussion 1210-1191

10. AhmadNA

LewisJD

GinsbergGG

HallerDG

MorrisJB

2001 Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 96 2609 2615

11. UenoH

KosugeT

MatsuyamaY

YamamotoJ

NakaoA

2009 A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101 908 915

12. EvansDB

VaradhacharyGR

CraneCH

SunCC

LeeJE

2008 Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 3496 3502

13. VaradhacharyGR

WolffRA

CraneCH

SunCC

LeeJE

2008 Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 3487 3495

14. KolbertCP

ChariS

SreekumarR

2008 Microarray technologies for gene transcript analysis in pancreatic cancer. Technol Cancer Res Treat 7 55 59

15. GrutzmannR

BorissH

AmmerpohlO

LuttgesJ

KalthoffH

2005 Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24 5079 5088

16. GrutzmannR

SaegerHD

LuttgesJ

SchackertHK

KalthoffH

2004 Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. Int J Colorectal Dis 19 401 413

17. GogginsM

2007 Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 34 303 310

18. GroteT

LogsdonCD

2007 Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 23 508 514

19. ToniniG

PantanoF

VincenziB

GabbrielliA

CoppolaR

2007 Molecular prognostic factors in patients with pancreatic cancer. Expert Opin Ther Targets 11 1553 1569

20. YehJJ

2009 Prognostic signature for pancreatic cancer: are we close? Future Oncol 5 313 321

21. KimHN

ChoiDW

LeeKT

LeeJK

HeoJS

2007 Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer. Pancreas 34 325 334

22. YangYH

DudoitS

LuuP

LinDM

PengV

2002 Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30 e15

23. TroyanskayaO

CantorM

SherlockG

BrownP

HastieT

2001 Missing value estimation methods for DNA microarrays. Bioinformatics 17 520 525

24. BenitoM

ParkerJ

DuQ

WuJ

XiangD

2004 Adjustment of systematic microarray data biases. Bioinformatics 20 105 114

25. TusherVG

TibshiraniR

ChuG

2001 Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98 5116 5121

26. HuZ

FanC

OhDS

MarronJS

HeX

2006 The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7 96

27. CampRL

Dolled-FilhartM

RimmDL

2004 X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10 7252 7259

28. YehJJ

RouthED

RubinasT

PeacockJ

MartinTD

2009 KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8 834 843

29. HoosA

Cordon-CardoC

2001 Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81 1331 1338

30. TroesterMA

LeeMH

CarterM

FanC

CowanDW

2009 Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res 15 7020 7028

31. AllinenM

BeroukhimR

CaiL

BrennanC

Lahti-DomeniciJ

2004 Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6 17 32

32. MuellerMM

FusenigNE

2004 Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4 839 849

33. ComoglioPM

TrusolinoL

2005 Cancer: the matrix is now in control. Nat Med 11 1156 1159

34. HerschkowitzJI

SiminK

WeigmanVJ

MikaelianI

UsaryJ

2007 Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8 R76

35. OhDS

TroesterMA

UsaryJ

HuZ

HeX

2006 Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24 1656 1664

36. LuY

LemonW

LiuPY

YiY

MorrisonC

2006 A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3 e467 doi:10.1371/journal.pmed.0030467

37. SohnTA

YeoCJ

CameronJL

KoniarisL

KaushalS

2000 Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4 567 579

38. HartelM

NarlaG

WenteMN

GieseNA

MartignoniME

2008 Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur J Cancer 44 1895 1903

39. YeoCJ

CameronJL

SohnTA

LillemoeKD

PittHA

1997 Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226 248 257; discussion 257-260

40. EppsteinerRW

CsikeszNG

McPheeJT

TsengJF

ShahSA

2009 Surgeon volume impacts hospital mortality for pancreatic resection. Ann Surg 249 635 640

41. YermilovI

BentremD

SekerisE

JainS

MaggardMA

2009 Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol 16 554 561

42. DeOliveiraML

WinterJM

SchaferM

CunninghamSC

CameronJL

2006 Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 244 931 937; discussion 937-939

43. Abou-AlfaGK

LetourneauR

HarkerG

ModianoM

HurwitzH

2006 Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24 4441 4447

44. Van CutsemE

VervenneWL

BennounaJ

HumbletY

GillS

2009 Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27 2231 2237

45. Crnogorac-JurcevicT

EfthimiouE

CapelliP

BlaveriE

BaronA

2001 Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20 7437 7446

46. Crnogorac-JurcevicT

EfthimiouE

NielsenT

LoaderJ

TerrisB

2002 Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21 4587 4594

47. KaranjawalaZE

IlleiPB

AshfaqR

InfanteJR

MurphyK

2008 New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 32 188 196

48. LoweAW

OlsenM

HaoY

LeeSP

Taek LeeK

2007 Gene expression patterns in pancreatic tumors, cells and tissues. PLoS ONE 2 e323 doi:10.1371/journal.pone.0000323

49. IshikawaM

YoshidaK

YamashitaY

OtaJ

TakadaS

2005 Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. Cancer Sci 96 387 393

50. SegaraD

BiankinAV

KenchJG

LanguschCC

DawsonAC

2005 Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 11 3587 3596

51. LogsdonCD

SimeoneDM

BinkleyC

ArumugamT

GreensonJK

2003 Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63 2649 2657

52. Iacobuzio-DonahueCA

AshfaqR

MaitraA

AdsayNV

Shen-OngGL

2003 Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63 8614 8622

53. Iacobuzio-DonahueCA

MaitraA

OlsenM

LoweAW

van HeekNT

2003 Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162 1151 1162

54. Iacobuzio-DonahueCA

MaitraA

Shen-OngGL

van HeekT

AshfaqR

2002 Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 160 1239 1249

55. Crnogorac-JurcevicT

MissiagliaE

BlaveriE

GangeswaranR

JonesM

2003 Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 201 63 74

56. GrutzmannR

PilarskyC

AmmerpohlO

LuttgesJ

BohmeA

2004 Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6 611 622

57. AngataT

KerrSC

GreavesDR

VarkiNM

CrockerPR

2002 Cloning and characterization of human Siglec-11. A recently evolved signaling that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J Biol Chem 277 24466 24474

58. JonesS

ZhangX

ParsonsDW

LinJC

LearyRJ

2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 1801 1806

59. DiFeoA

MartignettiJA

NarlaG

2009 The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 12 1 7

60. RamaswamyS

RossKN

LanderES

GolubTR

2003 A molecular signature of metastasis in primary solid tumors. Nat Genet 33 49 54

61. FidlerIJ

KripkeML

1977 Metastasis results from preexisting variant cells within a malignant tumor. Science 197 893 895

62. MinnAJ

GuptaGP

PaduaD

BosP

NguyenDX

2007 Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 104 6740 6745

63. MinnAJ

GuptaGP

SiegelPM

BosPD

ShuW

2005 Genes that mediate breast cancer metastasis to lung. Nature 436 518 524

64. MinnAJ

KangY

SerganovaI

GuptaGP

GiriDD

2005 Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115 44 55

65. NeoptolemosJP

DunnJA

StockenDD

AlmondJ

LinkK

2001 Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358 1576 1585

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2010 Číslo 7
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Získaná hemofilie - Povědomí o nemoci a její diagnostika

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa